AbbVie Current Liabilities vs Current Assets Analysis

ABBV Stock

USD 161.67 0.61 0.38%

Trend analysis of AbbVie Inc balance sheet accounts such as Total Assets of 81.2 B, Other Current Liabilities of 32.2 B or Total Current Liabilities of 39.7 B provides information on AbbVie's total assets, liabilities, and equity, which is the actual value of AbbVie Inc to its prevalent stockholders. By breaking down trends over time using AbbVie balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Non Current Assets Total

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

About AbbVie Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of AbbVie Inc at a specified time, usually calculated after every quarter, six months, or one year. AbbVie Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AbbVie and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which AbbVie currently owns. An asset can also be divided into two categories, current and non-current.

AbbVie Balance Sheet Chart

AbbVie Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how AbbVie Inc uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, AbbVie's Common Stock Shares Outstanding is fairly stable compared to the past year. Other Current Liabilities is likely to climb to about 32.2 B in 2024, whereas Total Stockholder Equity is likely to drop slightly above 7.1 B in 2024.

Common Stock Shares Outstanding Total Assets Other Current Liab Total Current Liabilities

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of AbbVie assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in AbbVie Inc books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on AbbVie balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of AbbVie Inc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from AbbVie's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AbbVie Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Sales General And Administrative To Revenue is likely to climb to 0.28 in 2024, whereas Selling General Administrative is likely to drop slightly above 8 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	38.8B	40.6B	45.5B	25.2B
Total Revenue	56.2B	58.1B	54.3B	33.8B

Gross Profit Total Revenue

AbbVie fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Property Plant Equipment	Long Term Debt
Common Stock Shares Outstanding		0.6	0.81	0.78	0.73	0.71	0.71	0.53	0.8	-0.29	0.67	0.81	-0.31	0.74	0.66	-0.37	0.44	0.69	0.65	0.74	0.5	0.89	0.07	0.66	0.7	0.36
Total Assets	0.6		0.76	0.85	0.35	0.9	0.97	0.96	0.81	0.31	0.98	0.84	0.29	0.93	0.99	-0.4	0.97	0.95	0.66	0.36	0.99	0.75	0.66	0.97	0.95	0.94
Other Current Liab	0.81	0.76		0.97	0.31	0.94	0.8	0.67	0.97	0.19	0.74	0.96	0.17	0.83	0.78	-0.4	0.7	0.83	0.58	0.36	0.74	0.95	0.51	0.71	0.8	0.66
Total Current Liabilities	0.78	0.85	0.97		0.3	0.97	0.88	0.79	0.97	0.22	0.84	0.96	0.2	0.87	0.86	-0.44	0.8	0.87	0.62	0.34	0.84	0.93	0.55	0.81	0.87	0.76
Total Stockholder Equity	0.73	0.35	0.31	0.3		0.26	0.48	0.29	0.26	-0.52	0.46	0.42	-0.55	0.46	0.4	-0.26	0.14	0.4	0.61	0.98	0.19	0.47	-0.24	0.48	0.47	0.07
Other Liab	0.71	0.9	0.94	0.97	0.26		0.87	0.84	0.96	0.29	0.87	0.93	0.27	0.86	0.9	-0.4	0.87	0.88	0.66	0.28	0.89	0.88	0.62	0.85	0.86	0.84
Property Plant And Equipment Net	0.71	0.97	0.8	0.88	0.48	0.87		0.92	0.81	0.15	0.98	0.89	0.13	0.96	0.98	-0.44	0.89	0.96	0.68	0.52	0.93	0.81	0.53	0.96	0.99	0.84
Net Debt	0.53	0.96	0.67	0.79	0.29	0.84	0.92		0.74	0.19	0.97	0.77	0.17	0.84	0.96	-0.28	0.95	0.87	0.57	0.31	0.95	0.64	0.52	0.98	0.89	0.93
Accounts Payable	0.8	0.81	0.97	0.97	0.26	0.96	0.81	0.74		0.22	0.79	0.93	0.2	0.85	0.83	-0.43	0.76	0.86	0.58	0.3	0.8	0.94	0.54	0.76	0.81	0.73
Cash	-0.29	0.31	0.19	0.22	-0.52	0.29	0.15	0.19	0.22		0.13	0.17	1.0	0.17	0.19	-0.28	0.46	0.22	-0.05	-0.51	0.42	0.1	0.91	0.1	0.16	0.53
Non Current Assets Total	0.67	0.98	0.74	0.84	0.46	0.87	0.98	0.97	0.79	0.13		0.84	0.11	0.92	0.99	-0.36	0.93	0.94	0.69	0.47	0.95	0.75	0.5	1.0	0.96	0.88
Other Assets	0.81	0.84	0.96	0.96	0.42	0.93	0.89	0.77	0.93	0.17	0.84		0.15	0.88	0.85	-0.46	0.77	0.88	0.59	0.48	0.81	0.92	0.51	0.82	0.88	0.74
Cash And Short Term Investments	-0.31	0.29	0.17	0.2	-0.55	0.27	0.13	0.17	0.2	1.0	0.11	0.15		0.15	0.17	-0.22	0.45	0.2	-0.07	-0.54	0.4	0.08	0.9	0.08	0.13	0.51
Net Receivables	0.74	0.93	0.83	0.87	0.46	0.86	0.96	0.84	0.85	0.17	0.92	0.88	0.15		0.95	-0.39	0.85	0.98	0.66	0.48	0.89	0.87	0.56	0.9	0.97	0.78
Good Will	0.66	0.99	0.78	0.86	0.4	0.9	0.98	0.96	0.83	0.19	0.99	0.85	0.17	0.95		-0.38	0.94	0.97	0.68	0.42	0.97	0.78	0.57	0.98	0.97	0.89
Short Term Investments	-0.37	-0.4	-0.4	-0.44	-0.26	-0.4	-0.44	-0.28	-0.43	-0.28	-0.36	-0.46	-0.22	-0.39	-0.38		-0.35	-0.42	-0.29	-0.29	-0.37	-0.41	-0.36	-0.35	-0.43	-0.33
Non Current Liabilities Total	0.44	0.97	0.7	0.8	0.14	0.87	0.89	0.95	0.76	0.46	0.93	0.77	0.45	0.85	0.94	-0.35		0.89	0.55	0.16	0.99	0.65	0.75	0.92	0.87	0.99
Inventory	0.69	0.95	0.83	0.87	0.4	0.88	0.96	0.87	0.86	0.22	0.94	0.88	0.2	0.98	0.97	-0.42	0.89		0.64	0.44	0.93	0.82	0.59	0.91	0.98	0.83
Other Current Assets	0.65	0.66	0.58	0.62	0.61	0.66	0.68	0.57	0.58	-0.05	0.69	0.59	-0.07	0.66	0.68	-0.29	0.55	0.64		0.57	0.59	0.65	0.29	0.68	0.69	0.46
Other Stockholder Equity	0.74	0.36	0.36	0.34	0.98	0.28	0.52	0.31	0.3	-0.51	0.47	0.48	-0.54	0.48	0.42	-0.29	0.16	0.44	0.57		0.21	0.49	-0.22	0.49	0.52	0.08
Total Liab	0.5	0.99	0.74	0.84	0.19	0.89	0.93	0.95	0.8	0.42	0.95	0.81	0.4	0.89	0.97	-0.37	0.99	0.93	0.59	0.21		0.7	0.73	0.93	0.92	0.97
Property Plant And Equipment Gross	0.89	0.75	0.95	0.93	0.47	0.88	0.81	0.64	0.94	0.1	0.75	0.92	0.08	0.87	0.78	-0.41	0.65	0.82	0.65	0.49	0.7		0.45	0.72	0.81	0.59
Total Current Assets	0.07	0.66	0.51	0.55	-0.24	0.62	0.53	0.52	0.54	0.91	0.5	0.51	0.9	0.56	0.57	-0.36	0.75	0.59	0.29	-0.22	0.73	0.45		0.47	0.54	0.77
Intangible Assets	0.66	0.97	0.71	0.81	0.48	0.85	0.96	0.98	0.76	0.1	1.0	0.82	0.08	0.9	0.98	-0.35	0.92	0.91	0.68	0.49	0.93	0.72	0.47		0.94	0.88
Property Plant Equipment	0.7	0.95	0.8	0.87	0.47	0.86	0.99	0.89	0.81	0.16	0.96	0.88	0.13	0.97	0.97	-0.43	0.87	0.98	0.69	0.52	0.92	0.81	0.54	0.94		0.82
Long Term Debt	0.36	0.94	0.66	0.76	0.07	0.84	0.84	0.93	0.73	0.53	0.88	0.74	0.51	0.78	0.89	-0.33	0.99	0.83	0.46	0.08	0.97	0.59	0.77	0.88	0.82

Click cells to compare fundamentals

AbbVie Account Relationship Matchups

AbbVie fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	1.5B	1.7B	1.8B	1.8B	1.8B	1.8B
Total Assets	89.1B	150.6B	146.5B	138.8B	134.7B	81.2B
Other Current Liab	10.4B	17.9B	19.8B	22.5B	30.7B	32.2B
Total Current Liabilities	15.6B	28.7B	35.2B	29.5B	37.8B	39.7B
Total Stockholder Equity	(8.2B)	13.1B	15.4B	17.3B	10.4B	7.1B
Other Liab	18.5B	30.4B	31.0B	31.7B	36.5B	38.3B
Property Plant And Equipment Net	3.0B	5.2B	5.1B	4.9B	5.0B	3.6B
Net Debt	26.8B	77.6B	66.9B	54.1B	46.6B	32.2B
Accounts Payable	1.5B	2.3B	2.9B	2.9B	3.7B	3.9B
Cash	39.9B	8.4B	9.7B	9.2B	12.8B	10.5B
Non Current Assets Total	39.6B	126.4B	118.6B	110.3B	101.7B	57.7B
Other Assets	1.9B	5.1B	4.1B	4.8B	5.6B	5.8B
Cash And Short Term Investments	39.9B	8.5B	9.8B	9.2B	12.8B	11.0B
Net Receivables	5.4B	8.8B	10.0B	11.3B	11.2B	6.8B
Good Will	15.6B	33.1B	32.4B	32.2B	32.3B	18.6B
Short Term Investments	0.0	30M	84M	28M	2M	1.9M
Liabilities And Stockholders Equity	89.1B	150.6B	146.5B	138.8B	134.7B	81.2B
Non Current Liabilities Total	81.7B	108.8B	95.9B	92.0B	86.5B	55.5B
Inventory	1.8B	3.3B	3.1B	3.6B	4.1B	2.2B
Other Stockholder Equity	(9.3B)	15.1B	15.2B	14.7B	13.6B	7.1B
Total Liab	97.3B	137.5B	131.1B	121.5B	124.3B	74.1B
Property Plant And Equipment Gross	3.0B	5.2B	10.7B	11.0B	11.6B	12.2B
Total Current Assets	49.5B	24.2B	27.9B	28.5B	33.0B	23.5B
Accumulated Other Comprehensive Income	(3.6B)	(3.1B)	(2.9B)	(2.2B)	(2.3B)	(2.4B)
Intangible Assets	18.6B	82.9B	76.0B	67.4B	55.6B	32.2B
Property Plant Equipment	3.0B	5.2B	5.1B	4.9B	5.7B	3.4B
Long Term Debt	63.0B	77.6B	64.2B	59.1B	52.2B	41.2B
Short Long Term Debt Total	66.7B	86.1B	76.7B	63.3B	59.4B	49.8B
Non Currrent Assets Other	1.2B	1.2B	1.9B	3.4B	6.6B	6.9B
Short Term Debt	3.8B	8.5B	12.5B	4.1B	7.2B	5.2B
Net Tangible Assets	(42.4B)	(102.9B)	(96.2B)	(82.3B)	(74.1B)	(77.8B)
Retained Earnings	4.7B	1.1B	3.1B	4.8B	(1B)	(950M)
Retained Earnings Total Equity	4.7B	1.1B	3.1B	4.8B	5.5B	3.4B
Long Term Debt Total	63.0B	77.6B	64.2B	59.1B	68.0B	50.1B
Capital Surpluse	15.2B	17.4B	18.3B	19.2B	22.1B	15.8B
Additional Paid In Capital	15.2B	17.4B	18.3B	19.2B	20.2B	15.0B

Pair Trading with AbbVie

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AbbVie position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AbbVie will appreciate offsetting losses from the drop in the long position's value.

Moving against AbbVie Stock

0.62	AMGN	Amgen Inc Financial Report 25th of April 2024	Pair Corr
0.58	BIIB	Biogen Inc Financial Report 23rd of April 2024	Pair Corr
0.48	ABVC	ABVC Biopharma	Pair Corr

The ability to find closely correlated positions to AbbVie could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AbbVie when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AbbVie - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AbbVie Inc to buy it.

The correlation of AbbVie is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AbbVie moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AbbVie Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for AbbVie can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether AbbVie Inc is a strong investment it is important to analyze AbbVie's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AbbVie's future performance. For an informed investment choice regarding AbbVie Stock, refer to the following important reports:

How To Invest In AbbVie

Details

Is AbbVie Stock a good investment?

Details

What is AbbVie's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for AbbVie Stock analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.

	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets

Is AbbVie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AbbVie. If investors know AbbVie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AbbVie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.67)

Dividend Share

5.99

Earnings Share

2.73

Revenue Per Share

30.723

Quarterly Revenue Growth

(0.05)

The market value of AbbVie Inc is measured differently than its book value, which is the value of AbbVie that is recorded on the company's balance sheet. Investors also form their own opinion of AbbVie's value that differs from its market value or its book value, called intrinsic value, which is AbbVie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AbbVie's market value can be influenced by many factors that don't directly affect AbbVie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AbbVie Current Liabilities vs Current Assets Analysis

About AbbVie Balance Sheet Analysis

AbbVie Balance Sheet Chart

Common Stock Shares Outstanding

Total Assets

Total Current Liabilities

AbbVie fundamental ratios Correlations

AbbVie Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AbbVie fundamental ratios Accounts

Pair Trading with AbbVie

Moving against AbbVie Stock

Complementary Tools for AbbVie Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Intangible Assets	+ 1.0	Non Current Assets Total
Good Will	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets
Property Plant Equipment	+ 0.99	Property Plant And Equipment Net
Good Will	+ 0.99	Non Current Assets Total

Cash And Short Term Investments	- 0.55	Total Stockholder Equity
Other Stockholder Equity	- 0.54	Cash And Short Term Investments
Cash	- 0.52	Total Stockholder Equity
Other Stockholder Equity	- 0.51	Cash
Short Term Investments	- 0.46	Other Assets
Short Term Investments	- 0.44	Property Plant And Equipment Net